After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
The drug titan reports Tuesday. Will a Dec. 24 cancer drug approval be an early Christmas gift?
Look for solid companies showing life.
Here are Thursday's top research calls, including upgrades for Anadarko Petroleum, GrubHub and Merck, and a downgrade for Pfizer.
Merck's (MRK) stock rating was increased to 'buy' at BofA/Merrill Lynch earlier today.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.